Genmab AS (WBO:GMAB) Cyclically Adjusted Book per Share: €44.78 (As of Mar. 2026)


WBO:GMAB Genmab AS WBO:GMAB
94 GF Score
Price €254.10
GF Value €309.01
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Cyclically Adjusted Book per Share?

Genmab AS WBO:GMAB +0.40% 94 Cyclically Adjusted Book per Share is €44.78 as of Mar. 2026. GuruFocus rates WBO:GMAB with a GF Score™ of 94/100 and a GF Value™ of €309.01 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Genmab AS's adjusted book value per share for the three months ended in Mar. 2026 was €80.059. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €44.78 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Genmab AS's average Cyclically Adjusted Book Growth Rate was 20.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 24.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 30.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Genmab AS was 40.30% per year. The lowest was 24.60% per year. And the median was 33.25% per year.

As of today (2026-07-09), Genmab AS's current stock price is €254.10. Genmab AS's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €44.78. Genmab AS's Cyclically Adjusted PB Ratio of today is 5.67.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Genmab AS was 39.38. The lowest was 4.40. And the median was 20.76.


Genmab AS  (WBO:GMAB) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Genmab AS's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=254.10/44.78
=5.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Genmab AS was 39.38. The lowest was 4.40. And the median was 20.76.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Genmab AS Cyclically Adjusted Book per Share Related Terms


Genmab AS Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Genmab AS's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Cyclically Adjusted Book per Share Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.63 22.28 28.22 35.37 43.05

Genmab AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.45 39.15 41.35 43.05 44.78

WBO:GMAB vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted PB Ratio falls into.


WBO:GMAB
94GF Score
Genmab AS WBO:GMAB
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genmab AS's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=80.059/121.6800*121.6800
=80.059

Current CPI (Mar. 2026) = 121.6800.

Genmab AS Quarterly Data

Book Value per Share CPI Adj_Book
201606 8.337 100.600 10.084
201609 8.771 100.200 10.651
201612 10.746 100.300 13.037
201703 11.089 101.200 13.333
201706 12.205 101.200 14.675
201709 11.889 101.800 14.211
201712 13.982 101.300 16.795
201803 14.295 101.700 17.103
201806 14.871 102.300 17.688
201809 15.396 102.400 18.295
201812 17.598 102.100 20.973
201903 17.578 102.900 20.786
201906 18.159 102.900 21.473
201909 25.622 102.900 30.298
201912 29.201 102.900 34.530
202003 29.585 103.300 34.849
202006 36.727 103.200 43.304
202009 37.858 103.500 44.508
202012 39.714 103.400 46.735
202103 40.691 104.300 47.472
202106 40.993 105.000 47.505
202109 43.168 105.800 49.647
202112 45.504 106.600 51.941
202203 47.093 109.900 52.141
202206 49.452 113.600 52.969
202209 54.057 116.400 56.509
202212 56.703 115.900 59.531
202303 56.996 117.300 59.124
202306 59.327 116.400 62.018
202309 63.213 117.400 65.518
202312 65.789 116.700 68.596
202403 66.391 118.400 68.230
202406 65.075 118.500 66.821
202409 67.827 118.900 69.413
202412 77.209 118.900 79.014
202503 77.338 120.200 78.290
202506 74.742 120.700 75.349
202509 79.586 121.600 79.638
202512 81.062 121.200 81.383
202603 80.059 121.680 80.059

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €44.78 mean?
Genmab AS (WBO:GMAB) has a Cyclically Adjusted Book per Share of €44.78 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Genmab AS and its competitors.
Is Genmab AS's Cyclically Adjusted Book per Share too high?
Genmab AS's current Cyclically Adjusted Book per Share is €44.78. Overall, Genmab AS has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Genmab AS's Cyclically Adjusted Book per Share of €44.78 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Genmab AS and its competitors. Genmab AS's current Cyclically Adjusted Book per Share is €44.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (WBO:GMAB) is currently considered Modestly Undervalued. The stock's GF Value™ is €309.01, compared to a current price of €254.10 — trading 17.8% below its estimated fair value. The current Cyclically Adjusted Book per Share is €44.78. Genmab AS's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Genmab AS (WBO:GMAB), the current Cyclically Adjusted Book per Share is €44.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (WBO:GMAB) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of €254.10 is trading 17.8% below its estimated GF Value™ of €309.01. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for WBO:GMAB:

  • Cyclically Adjusted Book per Share: €44.78
  • GF Value™: €309.01 vs. price of €254.10 (17.8% below fair value)
  • GF Score™: 94/100 with 5 warning signs

No single metric tells the full story. See the WBO:GMAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
94GF Score

Get the complete analysis for WBO:GMAB

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€254.10
Price
€309.01
GF Value